Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, Pemetrexed, and Bevacizumab in Light/Never Smoker NSCLC
NCT01344824Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Mar 2010
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, pemetrexed, carboplatin in non-small cell lung cancer (NSCLC), sponsored by UNC Lineberger Comprehensive Cancer Center. Started Mar 2010; status: completed.
02
Drugs
bevacizumabpemetrexedcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01344824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01344824.